The Anti-Diabetes Drugs market in Portugal has been experiencing steady growth over the past few years.
Customer preferences: Portuguese customers have been showing an increasing preference for anti-diabetes drugs that have fewer side effects and are more effective in controlling blood sugar levels. They are also more inclined towards drugs that are easy to administer and have a longer-lasting effect.
Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Portugal is the increasing adoption of combination therapies. This involves using two or more drugs to achieve better blood sugar control. Another trend is the rising popularity of GLP-1 receptor agonists, which are injectable drugs that help to stimulate insulin production. These drugs are becoming more popular due to their effectiveness in reducing weight and cardiovascular risk factors.
Local special circumstances: Portugal has one of the highest rates of diabetes in Europe, with over one million people suffering from the disease. This has led to increased government spending on healthcare, which has created a favorable environment for the Anti-Diabetes Drugs market. Additionally, the country has a well-established healthcare system that provides easy access to medication for patients.
Underlying macroeconomic factors: The Portuguese economy has been steadily recovering from the global financial crisis of 2008. This has led to increased consumer spending, which has positively impacted the Anti-Diabetes Drugs market. Additionally, the country has a growing elderly population, which is more susceptible to diabetes. This demographic shift has created a larger customer base for anti-diabetes drugs. Finally, the government's focus on healthcare has led to increased investment in research and development, which has resulted in the introduction of new and more effective drugs in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
